Enlivex Therapeutics Ltd. — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing. The company is an Israel-based clinical-stage biotechnology company developing Allocetra, an off-the-shelf cell therapy intended to reprogram macrophages. Financial statements are prepared under U.S. GAAP.
Business context and progress
Enlivex prioritized inflammatory and autoimmune programs—sepsis and osteoarthritis—in September 2023. It stopped internal oncology development and plans to pursue external partnerships or out-licensing for solid cancer applications. The company reduced its workforce by approximately 50% and expected the resulting savings and program changes to extend cash runway through the end of 2025.
- The randomized Phase II sepsis trial enrolled 120 patients by December 2023. In April 2024, the company reported topline results: treated patients had a reported 65% reduction in overall mortality versus expected mortality based on external data, and SOFA score reductions varied by infection source. The filing notes important treatment/control imbalances, limiting interpretation of subgroup comparisons; the reported mortality comparison is not presented as a definitive placebo-controlled efficacy result.
- In 2023, the company dosed the first patient in an investigator-initiated Phase I/II study of 12 patients with end-stage knee osteoarthritis. A company-sponsored, randomized, placebo-controlled Phase I/II osteoarthritis study of up to 160 patients began in 2024. The company targeted topline results from the 12-patient study by Q3 2024 and from the randomized study by Q3 2025.
Financial results and liquidity
| Metric (US$ millions, except per-share data) | 2023 | 2022 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development expense, net | 19.012 | 18.693 |
| General and administrative expense | 6.139 | 7.104 |
| Loss on assets held for sale | 4.244 | — |
| Operating loss | 29.395 | 25.797 |
| Net loss | 29.068 | 31.060 |
| Basic and diluted loss per share | $1.56 | $1.69 |
| Net cash used in operating activities | 23.523 | 23.953 |
Gross margin and conventional operating margins are not meaningful because the company had no revenue. Net loss improved 6% year over year, despite a 14% increase in operating loss, principally because net finance results improved from a $5.263 million expense in 2022 to $0.327 million of income in 2023. The operating loss included the $4.244 million held-for-sale asset charge; R&D expense rose 2% and G&A expense fell 14%.
- Cash and deposits: At year-end, cash and cash equivalents were $0.813 million and short-term interest-bearing deposits were $26.507 million. Working capital was approximately $27.7 million; total assets were $36.831 million.
- Cash flow: Operating activities used $23.523 million. Investing activities used $25.968 million, mainly reflecting investment in short-term bank deposits; financing activities provided $0.360 million, from ATM share sales.
- Debt and liabilities: The filing does not report conventional borrowings. Total liabilities were $6.747 million, including $1.032 million of operating lease liabilities. The company had a contingent IIA royalty obligation of approximately $9.6 million, including interest; royalties are generally payable from relevant product sales.
- Capital and dilution: The company sold 124,171 shares under its ATM program in 2023 for $0.360 million net proceeds. It had 18,598,555 shares outstanding at year-end. A $1.5 million share repurchase program was authorized, but no shares were repurchased in 2023.
Outlook, risks and unusual items
Management expected existing resources to support planned operations through the end of 2025, while stating that substantial additional financing would be needed for further development and regulatory approval. The audited financial-statement discussion says resources were expected to cover at least 12 months from issuance; it also states that, without additional capital, substantial doubt exists about the company’s ability to continue activities beyond the end of 2025. There are no committed external funding sources, and the company may need equity, debt, grants, partnerships or licensing proceeds.
Key risks include clinical and regulatory failure or delay, the interpretive limitations of the Phase II sepsis results, manufacturing and blood-supply quality risks, reliance on third parties, competition, potential shareholder dilution, and geopolitical disruption in Israel. The company also disclosed foreign-exchange exposure: a 5% change in the U.S. dollar against the NIS would change expenses by approximately $0.802 million. It had no foreign-currency hedging arrangements at year-end. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; liquidity and clinical-trial accruals were identified as critical audit matters.
After year-end, the company agreed to sell equipment at its Yavne manufacturing facility and transfer the lease obligations to BioHarvest for NIS 13.0 million (approximately $3.5 million), payable in installments. The agreement became effective April 1, 2024; the initial NIS 4.0 million payment was received April 2, 2024. The 2023 accounts had already recognized a $4.244 million loss on the held-for-sale asset group.
Important facts for investors to verify
- Review the full Phase II sepsis dataset, including placebo comparisons, patient-group imbalances, analysis population, statistical methods and safety results; distinguish the reported external-benchmark mortality comparison from a controlled treatment effect.
- Check actual cash burn, deposit availability and subsequent financing against the stated runway, and assess the financing needed for planned trials and regulatory work.
- Verify milestone progress and enrollment in both osteoarthritis trials against the stated readout targets.
- Track receipt of the Yavne sale installments and any conditions or payment risks, as well as the effect of the lease transfer on costs and manufacturing capacity.
- Assess potential dilution from ATM or other financing and the implications of the IIA royalty and technology-transfer restrictions.